Drug Treatment of Epilepsy: Outlines, Criticism and Perspectives

Ettore Beghi, Rocco Di Mascio, Gianni Tognoni

Research output: Contribution to journalArticle

Abstract

This article focuses on important aspects relevant to the assessment of antiepileptic treatment and critically reviews the existing knowledge in this area. The principal variables considered are the commencement of treatment, choice of appropriate drug, efficacy of monotherapy, and cessation of treatment. When seizure recurrences after the first unprovoked seizure are considered, contradictory data have been provided on the role of early (i.e. after the first seizure) therapy in preventing relapses. The choice of the appropriate drug seems to be dictated more by clinical toxicity than by truly greater efficacy since there is no evidence of significant differences in efficacy among the ‘major’ anticonvulsants such as phenytoin, phenobarbitone, carbamazepine and primidone. Monotherapy is the preferred treatment, at least in previously untreated patients, since up to 90% of cases are completely controlled after variable periods of observation. Cessation of therapy after prolonged seizure control is followed by relapses in a varying percentage of cases depending on several factors, among which is the duration of the period of control. As yet, a definitive comparison of the available information has been prevented by major methodological differences and by partial investigation of the various aspects of the care of the patient with epilepsy. To provide a tentative answer to some of the open questions concerning the impact of anticonvulsant therapy on the prognosis of the disease, an alternative approach has been proposed, based on the active surveillance of a cohort of newly referred patients started on monotherapy in routine care conditions over a period of more than 5 years. The feasibility of this approach is being tested in a multicentre prospective study currently in progress in Italy.

Original languageEnglish
Pages (from-to)249-265
Number of pages17
JournalDrugs
Volume31
Issue number3
DOIs
Publication statusPublished - 1986

Fingerprint

Drug therapy
Anticonvulsants
Epilepsy
Seizures
Primidone
Pharmaceutical Preparations
Carbamazepine
Phenytoin
Phenobarbital
Recurrence
Toxicity
Therapeutics
Withholding Treatment
Italy
Multicenter Studies
Patient Care
Observation
Prospective Studies

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Health, Toxicology and Mutagenesis
  • Toxicology

Cite this

Drug Treatment of Epilepsy : Outlines, Criticism and Perspectives. / Beghi, Ettore; Di Mascio, Rocco; Tognoni, Gianni.

In: Drugs, Vol. 31, No. 3, 1986, p. 249-265.

Research output: Contribution to journalArticle

Beghi, Ettore ; Di Mascio, Rocco ; Tognoni, Gianni. / Drug Treatment of Epilepsy : Outlines, Criticism and Perspectives. In: Drugs. 1986 ; Vol. 31, No. 3. pp. 249-265.
@article{4dea0a5502f84d5499632b66636296b7,
title = "Drug Treatment of Epilepsy: Outlines, Criticism and Perspectives",
abstract = "This article focuses on important aspects relevant to the assessment of antiepileptic treatment and critically reviews the existing knowledge in this area. The principal variables considered are the commencement of treatment, choice of appropriate drug, efficacy of monotherapy, and cessation of treatment. When seizure recurrences after the first unprovoked seizure are considered, contradictory data have been provided on the role of early (i.e. after the first seizure) therapy in preventing relapses. The choice of the appropriate drug seems to be dictated more by clinical toxicity than by truly greater efficacy since there is no evidence of significant differences in efficacy among the ‘major’ anticonvulsants such as phenytoin, phenobarbitone, carbamazepine and primidone. Monotherapy is the preferred treatment, at least in previously untreated patients, since up to 90{\%} of cases are completely controlled after variable periods of observation. Cessation of therapy after prolonged seizure control is followed by relapses in a varying percentage of cases depending on several factors, among which is the duration of the period of control. As yet, a definitive comparison of the available information has been prevented by major methodological differences and by partial investigation of the various aspects of the care of the patient with epilepsy. To provide a tentative answer to some of the open questions concerning the impact of anticonvulsant therapy on the prognosis of the disease, an alternative approach has been proposed, based on the active surveillance of a cohort of newly referred patients started on monotherapy in routine care conditions over a period of more than 5 years. The feasibility of this approach is being tested in a multicentre prospective study currently in progress in Italy.",
author = "Ettore Beghi and {Di Mascio}, Rocco and Gianni Tognoni",
year = "1986",
doi = "10.2165/00003495-198631030-00003",
language = "English",
volume = "31",
pages = "249--265",
journal = "Drugs",
issn = "0012-6667",
publisher = "Adis International Ltd",
number = "3",

}

TY - JOUR

T1 - Drug Treatment of Epilepsy

T2 - Outlines, Criticism and Perspectives

AU - Beghi, Ettore

AU - Di Mascio, Rocco

AU - Tognoni, Gianni

PY - 1986

Y1 - 1986

N2 - This article focuses on important aspects relevant to the assessment of antiepileptic treatment and critically reviews the existing knowledge in this area. The principal variables considered are the commencement of treatment, choice of appropriate drug, efficacy of monotherapy, and cessation of treatment. When seizure recurrences after the first unprovoked seizure are considered, contradictory data have been provided on the role of early (i.e. after the first seizure) therapy in preventing relapses. The choice of the appropriate drug seems to be dictated more by clinical toxicity than by truly greater efficacy since there is no evidence of significant differences in efficacy among the ‘major’ anticonvulsants such as phenytoin, phenobarbitone, carbamazepine and primidone. Monotherapy is the preferred treatment, at least in previously untreated patients, since up to 90% of cases are completely controlled after variable periods of observation. Cessation of therapy after prolonged seizure control is followed by relapses in a varying percentage of cases depending on several factors, among which is the duration of the period of control. As yet, a definitive comparison of the available information has been prevented by major methodological differences and by partial investigation of the various aspects of the care of the patient with epilepsy. To provide a tentative answer to some of the open questions concerning the impact of anticonvulsant therapy on the prognosis of the disease, an alternative approach has been proposed, based on the active surveillance of a cohort of newly referred patients started on monotherapy in routine care conditions over a period of more than 5 years. The feasibility of this approach is being tested in a multicentre prospective study currently in progress in Italy.

AB - This article focuses on important aspects relevant to the assessment of antiepileptic treatment and critically reviews the existing knowledge in this area. The principal variables considered are the commencement of treatment, choice of appropriate drug, efficacy of monotherapy, and cessation of treatment. When seizure recurrences after the first unprovoked seizure are considered, contradictory data have been provided on the role of early (i.e. after the first seizure) therapy in preventing relapses. The choice of the appropriate drug seems to be dictated more by clinical toxicity than by truly greater efficacy since there is no evidence of significant differences in efficacy among the ‘major’ anticonvulsants such as phenytoin, phenobarbitone, carbamazepine and primidone. Monotherapy is the preferred treatment, at least in previously untreated patients, since up to 90% of cases are completely controlled after variable periods of observation. Cessation of therapy after prolonged seizure control is followed by relapses in a varying percentage of cases depending on several factors, among which is the duration of the period of control. As yet, a definitive comparison of the available information has been prevented by major methodological differences and by partial investigation of the various aspects of the care of the patient with epilepsy. To provide a tentative answer to some of the open questions concerning the impact of anticonvulsant therapy on the prognosis of the disease, an alternative approach has been proposed, based on the active surveillance of a cohort of newly referred patients started on monotherapy in routine care conditions over a period of more than 5 years. The feasibility of this approach is being tested in a multicentre prospective study currently in progress in Italy.

UR - http://www.scopus.com/inward/record.url?scp=0022630598&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022630598&partnerID=8YFLogxK

U2 - 10.2165/00003495-198631030-00003

DO - 10.2165/00003495-198631030-00003

M3 - Article

C2 - 3519174

AN - SCOPUS:0022630598

VL - 31

SP - 249

EP - 265

JO - Drugs

JF - Drugs

SN - 0012-6667

IS - 3

ER -